ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

January 17, 2024

The Centers for Medicare & Medicaid Services (CMS) issued its rule requiring federal health plans—including Medicare Advantage plans, Medicaid plans, and Qualified Health Plans (QHP) on Federally Facilitated Exchanges (FFEs)— to establish an electronic prior authorization process that will be integrated into providers’ workflows.

January 16, 2024

The Association for Clinical Oncology (ASCO) submitted comments to the Centers for Medicare & Medicaid Services (CMS) in response to two proposed rules: the 2025 Medicare Advantage and Part D proposed rule and the 2025 Notice of Benefit and Payment Parameters proposed rule. ASCO’s comments support provisions that address utilization management and health equity, which have the potential to improve access to care for the cancer community.

January 16, 2024

In a response to the Establishment of Disincentives for Health Care Providers That Have Committed Information Blocking proposed rule, the Association for Clinical Oncology (ASCO) urges the Centers for Medicare & Medicaid Services (CMS) and the Office of the National Coordinator for Health Information Technology (ONC) not to implement the disincentives as proposed. ASCO also asks CMS for further clarification on the enforcement process, and the Association supports establishing a meaningful opportunity for appeals.

January 16, 2024

As of January 1, 2024, oncology practitioners can bill and receive Medicare payment for connecting patients to navigation services. The Centers for Medicare & Medicaid Services adopted two billing codes for Principle Illness Navigation services: G0023 for the initial 60 minutes per patient per month, and G0024 to capture each additional 30 minutes per patient per month. The American Society of Clinical Oncology has received many inquiries about coding and billing for these new services and has made resources available for the oncology community.

January 12, 2024

On January 12, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer.

January 12, 2024

State legislative sessions are beginning across the country. While ASCO anticipates lighter legislative agendas at the state level in2024, given the upcoming elections in November, the Association will continue to work with the state affiliates and our coalition partners to educate lawmakers on the issues impacting cancer care.

January 9, 2024

A paper published January 9, 2024 in the journal Cancer details three calls-to-action that the oncology research and clinical care communities should implement to expand access to clinical trials and improve inclusivity to enable more people with cancer to participate in clinical trials closer to home.

Pages